Lyndsay M Murray

List of Publications by Year
in descending order

25 papers	1,505 citations	471477 17 h-index	580810 25 g-index
25 all docs	25 docs citations	25 times ranked	1451 citing authors

#	Article	IF	Citations
1	Selective vulnerability of motor neurons and dissociation of pre- and post-synaptic pathology at the neuromuscular junction in mouse models of spinal muscular atrophy. Human Molecular Genetics, 2008, 17, 949-962.	2.9	333
2	Alternative Splicing Events Are a Late Feature of Pathology in a Mouse Model of Spinal Muscular Atrophy. PLoS Genetics, 2009, 5, e1000773.	3.5	210
3	A critical smn threshold in mice dictates onset of an intermediate spinal muscular atrophy phenotype associated with a distinct neuromuscular junction pathology. Neuromuscular Disorders, 2012, 22, 263-276.	0.6	116
4	A novel function for the survival motoneuron protein as a translational regulator. Human Molecular Genetics, 2013, 22, 668-684.	2.9	106
5	Pre-symptomatic development of lower motor neuron connectivity in a mouse model of severe spinal muscular atrophy. Human Molecular Genetics, 2010, 19, 420-433.	2.9	98
6	Reversible molecular pathology of skeletal muscle in spinal muscular atrophy. Human Molecular Genetics, 2011, 20, 4334-4344.	2.9	89
7	Transcriptional profiling of differentially vulnerable motor neurons at pre-symptomatic stage in the Smn 2b/- mouse model of spinal muscular atrophy. Acta Neuropathologica Communications, 2015, 3, 55.	5.2	61
8	Defects in neuromuscular junction remodelling in the Smn2B/â^' mouse model of spinal muscular atrophy. Neurobiology of Disease, 2013, 49, 57-67.	4.4	59
9	Myogenic program dysregulation is contributory to disease pathogenesis in spinal muscular atrophy. Human Molecular Genetics, 2014, 23, 4249-4259.	2.9	59
10	Defects in pancreatic development and glucose metabolism in SMN-depleted mice independent of canonical spinal muscular atrophy neuromuscular pathology. Human Molecular Genetics, 2014, 23, 3432-3444.	2.9	55
11	Temporal and tissue-specific variability of SMN protein levels in mouse models of spinal muscular atrophy. Human Molecular Genetics, 2018, 27, 2851-2862.	2.9	55
12	PLAA Mutations Cause a Lethal Infantile Epileptic Encephalopathy by Disrupting Ubiquitin-Mediated Endolysosomal Degradation of Synaptic Proteins. American Journal of Human Genetics, 2017, 100, 706-724.	6.2	37
13	Interventions Targeting Glucocorticoid-KrÃ¼ppel-like Factor 15-Branched-Chain Amino Acid Signaling Improve Disease Phenotypes in Spinal Muscular Atrophy Mice. EBioMedicine, 2018, 31, 226-242.	6.1	37
14	Comparison of independent screens on differentially vulnerable motor neurons reveals alpha-synuclein as a common modifier in motor neuron diseases. PLoS Genetics, 2017, 13, e1006680.	3.5	36
15	Loss of translation elongation factor (eEF1A2) expression in vivo differentiates between Wallerian degeneration and dyingâ€back neuronal pathology. Journal of Anatomy, 2008, 213, 633-645.	1.5	28
16	Pathogenic commonalities between spinal muscular atrophy and amyotrophic lateral sclerosis: Converging roads to therapeutic development. European Journal of Medical Genetics, 2018, 61, 685-698.	1.3	28
17	Reduced P53 levels ameliorate neuromuscular junction loss without affecting motor neuron pathology in a mouse model of spinal muscular atrophy. Cell Death and Disease, 2019, 10, 515.	6.3	21
18	The Smn-Independent Beneficial Effects of Trichostatin A on an Intermediate Mouse Model of Spinal Muscular Atrophy. PLoS ONE, 2014, 9, e101225.	2.5	21

#	Article	IF	Citations
19	Dissection of the Transversus Abdominis Muscle for Whole-mount Neuromuscular Junction Analysis. Journal of Visualized Experiments, 2014, , e51162.	0.3	17
20	Altered mitochondrial bioenergetics are responsible for the delay in Wallerian degeneration observed in neonatal mice. Neurobiology of Disease, 2019, 130, 104496.	4.4	15
21	The response of neuromuscular junctions to injury is developmentally regulated. FASEB Journal, 2011, 25, 1306-1313.	0.5	10
22	Synaptic withdrawal following nerve injury is influenced by postnatal maturity, muscleâ€specific properties, and the presence of underlying pathology in mice. Journal of Anatomy, 2020, 237, 263-274.	1.5	4
23	Motor unit recovery following Smn restoration in mouse models of spinal muscular atrophy. Human Molecular Genetics, 2022, 31, 3107-3119.	2.9	4
24	A reduction in the human adenovirus virion size through use of a shortened fibre protein does not enhance muscle transduction following systemic or localised delivery in mice. Virology, 2014, 468-470, 444-453.	2.4	3
25	How far away is spinal muscular atrophy gene therapy?. Expert Review of Neurotherapeutics, 2015, 15, 965-968.	2.8	3